WTI原油日內跌3.00%，現報74.93美元/桶。

China's National Medical Products Administration granted priority-review approval to Kaixing Life Sciences (Shanghai) Co. for Shurui Jiaolunsai injection, marketed as Kailimei, for CLDN18.2‑positive, HER2‑negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have progressed after at least two prior lines of therapy. The approval adds a new later‑line treatment option for this biomarker‑defined patient population.

A股保險股集體上漲，新華保險、中國人壽漲超4%，中國平安漲超2%，中國人保、中國太保跟漲。